Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...

(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...